Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Sunday, November 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Complement-Based Drug Development Summit leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Sreoshi Chatterjee
  • Page 43

Author

Sreoshi Chatterjee 452 posts 0 comments

OPTIMAPHARM Obtains CZECH MKS Research

Jan 15, 2018
Following the league of leading in the markets of  clinical research organizations, Optimapharm obtained Czech CRO company MKS research. Following the acquisition , Optimapharm will…
Read More...

Richard Paulson appointed as Vice-President and CEO by Ipsen North America

Jan 15, 2018
Ipsen declared the appointment of Richard Paulson as Executive Vice-president and Chief Executive Officer of Ipsen North America accountable for  commercial operations throughout the…
Read More...

Fast Track Designation granted to Concert Pharmaceutical’s CTP-543 for Alopecia Areata

Jan 15, 2018
Concert Pharmaceuticals asserted that the U.S FDA has offered Fast Track designation for CTP-543, inhibitor for treatment of moderate-to severe Alopecia Areata discerned as a serious…
Read More...

Fresenius Kabi Launches Bortezomib injection in U.S

Jan 15, 2018
Fresenius Kabi confirmed the availability of Bortezomib for injection  in the United States. Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg…
Read More...

FDA approves GSK’s FLUARIX QUADRIVALENT

Jan 15, 2018
GSK asserted that it has received approval from the US FDA center for biologics Evaluation and Research thereby hinting at the usage of FLUARIX QUADRIVALENT in persons 6 months and…
Read More...

FDA sanctions use of Lynparza to treat Breast Cancer with inherited genetic mutation

Jan 15, 2018
FDA approved use of Lynparza (olaparib tablets) to include treatment of patients with certain types of  Breast Cancer that have become widespread and whose tumors possess inherited…
Read More...

Dr. Chiang Syin appointed Chief Quality Officer of Wuxi Biologics

Jan 15, 2018
Gobal open-access biologics technology platform company, Wuxi Biologics declares that Dr. Chiang Syin has been appointed by Wuxi Biologics as its Chief Quality Officer accountable for…
Read More...

Boston Scientific declares affirmative outcomes for WHISPER RCT

Jan 15, 2018
Boston Scientific Corporation declared optimistic outcomes from the WHISPER randomized controlled Trial.According to the data presented at the 2018 Annual meeting of the North American …
Read More...

Sci-Engi-Medco Solutions secures SBIR Phase 1 Contract

Jan 15, 2018
Private cancer drug discovery and development company, Sci- Engi-Medco Solutions Inc. (SEMCO) has secured a Small Business Innovation Research Phase 1 contract from the National Cancer…
Read More...

Rgenix declares Clinical and Pre-Clinical results

Jan 12, 2018
Clinical Biopharmaceutical Company Rgenix declared the Clinical and pre-Clinical results by research collaborators at Rgenix and Rockefeller University disclosing that Liver-X…
Read More...
Prev Next
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
8th RNAi-Based Therapeutics Summit
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
RNA-Targeted Drug Discovery & Development Summit
RNA-Based Therapeutics & Vaccines Summit South Korea
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Adalvo Acquires Enzene’s Romiplostim Biosimilar Programme
  • Appian and PSI CRO Partner to Bring AI Into Clinical Trials
  • Pfizer Partners With Edison Scientific to Accelerate AI-Driven Drug Research
  • Dren Bio Raises $350M to Advance Experimental Blood Cancer Drug
  • Glenmark Opens Major US Pharmaceutical Distribution Center in Pennsylvania

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.